Pretreatment Neutrophil-to-Lymphocyte Ratio and Lactate Dehydrogenase Predict the Prognosis of Metastatic Cervical Cancer Treated with Combination Immunotherapy

Table 1

General characteristics of patients with metastatic cervical cancer treated with combination immunotherapy.

Variables	(%)
Median age, years (range)	51 (29–77)
Histology
Squamous cell carcinoma	54 (77.14)
Adenocarcinoma or others	16 (22.86)
Disease status
Local recurrence	27 (38.57)
Distant metastasis	43 (61.43)
Prior radiotherapy
Yes	56 (80.00)
No	14 (20.00)
Line of immunotherapy
First-line or second-line	46 (65.71)
Third-line or more	24 (34.29)
NLR	5.17 (3.19–9.16)
PLR	270.50 (174.19–363.49)
MLR	0.51 (0.31–0.78)
SCC-Ag (ng/mL)	2.85 (0.90–14.10)
AGR	1.50 (1.30–1.63)
LDH (U/L)	166.50 (146.75–195.75)
ALP (U/L)	87.50 (70.00–106.00)

Abbreviations: AGR, albumin-to-globulin ratio; ALP, alkaline phosphatase; LDH, lactate dehydrogenase; MLR, monocyte-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; SCC-Ag, squamous cell carcinoma-associated antigen.